A decade of progress in juvenile idiopathic arthritis treatments and outcomes in Canada: results from ReACCh-Out and the CAPRI registry
An erratum to this article was published (Rheumatology (Oxford), 1 Sep 2024 ↗)
Authors' conclusion
Although baseline disease characteristics were comparable in the 2005-2010 and 2017-2021 cohorts, cDMARD and bDMARD use increased with a concurrent increase in minimally active and inactive disease. Improvements in parent and patient-reported outcomes were smaller than improvements in disease activity.
Study context
- Population
- Patients with juvenile idiopathic arthritis (JIA) in Canada enrolled within three months of diagnosis
- Participants
- 721 vs 1,128
- Exposure
- 2017-2021 inception cohort vs 2005-2010 inception cohort
- 2017-2021n = 721
- 2005-2010n = 1,128reference
- Outcome
- Cumulative incidences of drug starts and outcome attainment
- Follow-up
- Within 70 weeks of diagnosis
Methodological detailscomparison of two registry cohorts, multicentre registries (ReACCh-Out and CAPRI), Kaplan-Meier survival analysis, multivariable Cox regression
- Comparison of two registry cohorts
- Multicentre registries (ReACCh-Out and CAPRI)
- Kaplan-Meier survival analysis
- Multivariable Cox regression
Main finding
As reported in the abstract
Started a bDMARD · 70 weeks
Observational data: associations, not effects.
Further findings
| Outcome | 2005-2010 | 2017-2021 |
|---|---|---|
| Started a cDMARD (cumulative incidence) · 70 weeks | 43% (95% CI 40–47) | 60% (95% CI 56–64) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
A decade of progress in juvenile idiopathic arthritis treatments and outcomes in Canada: results from ReACCh-Out and the CAPRI registry. Rheumatology (Oxford). Published 18 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →